DIFFERENCES IN IFN-GAMMA AND SARS-COV-2 SPECIFIC IgG LEVEL IN mRNA BNT162B2 (PFIZER-BIONTECH) VACCINATED NAIVE AND COVID-19 RECOVERED INDIVIDUALS FROM ZAKHO DISTRICT, DUHOK, IRAQ
Keywords:
Covid-19, Anti-SARS-Cov-2 IgG, IFN-γ, BNT162B2 Vaccine, Naive, Recovered
Abstract
COVID-19 has caused massive public health threats worldwide, leading to the development of effective vaccines to control the epidemic. Real-world evidence confirms the efficacy of vaccinations against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to evaluate and compare the titer of anti-SARS-CoV-2 IgG antibodies against the S1 subunit of the virus’s spike protein as a marker of the humoral response and the concentration of interferon-gamma as an indicator of cellular response in naive and recovered individuals. The study included 176 individuals, 88 (50%) were naïve, and 88 (50%) had a previous history of exposure to SARS-CoV-2 with or without symptoms. The serum concentration of IgG and IFN-γ were measured two weeks after the second dose of the BNT162B2 mRNA vaccine in naive and recovered individuals using enzyme-linked immunosorbent assays. The concentration of anti-SARS-CoV-IgG and IFN-γ was significantly higher in recovered participants compared to naive. Moreover, the concentration of anti-SARS-CoV-IgG and IFN-γ was significantly associated with severe cases. Our results suggested that the second dose of the BNT162b2 mRNA vaccine provides a protective humoral and cellular immune response to almost all individuals. While inducing a more robust immune response in recovered individuals, indicates that a single dose of the vaccine may be sufficient for symptomatic recovered individuals
Downloads
Download data is not yet available.
References
Agrati, C., Castilletti, C., Goletti, D., Meschi, S., Sacchi, A., Matusali, G., Bordoni, V., Petrone, L., Lapa, D., Notari, S., Vanini, V., Colavita, F., Aiello, A., Agresta, A., Farroni, C., Grassi, G., Leone, S., Vaia, F., Capobianchi, M. R., Puro, V. (2021). Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms, 9(6), 1315. doi: 10.3390/MICROORGANISMS9061315
Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., Austin, J., Brown, R., Skelly, D., Gillson, N., Dobson, S. L., Cross, A., Sandhar, G., Kilby, J. A., Tyerman, J. K., … Chalk, J. (2022). T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe, 3(1), e21–e31. doi: 10.1016/S2666-5247(21)00275-5
Buonfrate, D., Piubelli, C., Gobbi, F., Martini, D., Bertoli, G., Ursini, T., Moro, L., Ronzoni, N., Angheben, A., Rodari, P., Cardellino, C., Tamarozzi, F., Tais, S., Rizzi, E., Degani, M., Deiana, M., Prato, M., Silva, R., & Bisoffi, Z. (2021). Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clinical Microbiology and Infection, 27(12), 1845–1850. doi: 10.1016/j.cmi.2021.07.024
Chen, Z., & John Wherry, E. (2020). T cell responses in patients with COVID-19. Nature Reviews Immunology, 20(9), 529–536. doi: 10.1038/s41577-020-0402-6
Claro, F., Silva, D., Rodriguez, M., Rangel, H. R., & de Waard, J. H. (2021). Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 111, 261–266. doi: 10.1016/J.IJID.2021.07.070
Cocomazzi, G., Piazzolla, V., Squillante, M. M., Antinucci, S., Giambra, V., Giuliani, F., Maiorana, A., Serra, N., & Mangia, A. (2021). Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. Vaccines, 9(8), 913. doi: 10.3390/VACCINES9080913
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., Nagata, B. M., Andersen, H., Martinez, D. R., Noe, A. T., Douek, N., Donaldson, M. M., Nji, N. N., Alvarado, G. S., Edwards, D. K., … Graham, B. S. (2020). Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 383(16), 1544–1555. doi: 10.1056/NEJMoa2024671
Demonbreun, A. R., Sancilio, A., Velez, M. P., Ryan, D. T., Saber, R., Vaught, L. A., Reiser, N. L., Hsieh, R. R., D’Aquila, R. T., Mustanski, B., McNally, E. M., & McDade, T. W. (2021). Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine, 38, 101018. doi: 10.1016/j.eclinm.2021.101018
Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J. C., Frias, E. C., Stewart, J. L., Van Eyk, J. E., Braun, J. G., Cheng, S., & Sobhani, K. (2021). Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine, 27(6), 981–984. doi: 10.1038/s41591-021-01325-6
Fraley, E., Lemaster, C., Khanal, S., Banerjee, D., Pastinen, T., Grundberg, E., Selvarangan, R., & Bradley, T. (2022). The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clinical Infectious Diseases, 75(1), e902–e904. doi: 10.1093/CID/CIAB850
Gelanew, T., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Tefer, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., Bayih, A. G., Taffesse, F. G., Mihret, A., & Abdissa, A. (2022). A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals. Research Square, 10(6). doi: 10.21203/RS.3.RS-1250175/V1
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., Thorsteinsdottir, B., Kristjansdottir, S., Birgisdottir, K., Kristinsdottir, A. M., Sigurdsson, M. I., Arnadottir, G. A., Ivarsdottir, E. V., Andresdottir, M., Jonsson, F., … Stefansson, K. (2020). Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine, 383(18), 1724–1734. doi: 10.1056/NEJMOA2026116
Hasan, A., Al-Ozairi, E., Al-Baqsumi, Z., Ahmad, R., & Al-Mulla, F. (2021). Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, Volume 10, 63–85. doi: 10.2147/itt.s280706
Holder, K. A., Ings, D. P., Harnum, D. O. A., Russell, R. S., & Grant, M. D. (2022). Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. Npj Vaccines 2022 7:1, 7(1), 1–13. doi: 10.1038/s41541-022-00546-1
Ivanova, E. N., Devlin, J. C., Buus, T. B., Koide, A., Shwetar, J., Cornelius, A., Samanovic, M. I., Herrera, A., Mimitou, E. P., Zhang, C., Desvignes, L., Odum, N., Smibert, P., Ulrich, R. J., Mulligan, M. J., Koide, S., Ruggles, K. V., Herati, R. S., & Koralov, S. B. (2021). SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. MedRxiv. doi: 10.1101/2021.04.20.21255677
Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516–527. doi: 10.1038/s41586-020-2798-3
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G., Jurczyszak, D., Matthews, J. C., … Simon, V. (2021). Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New England Journal of Medicine, 384(14), 1372–1374. doi: 10.1056/NEJMC2101667
Lange, A., Borowik, A., Bocheńska, J., Rossowska, J., & Jaskuła, E. (2021). Immune Response to COVID-19 mRNA Vaccine—A Pilot Study. Vaccines, 9(5), 488. doi: 10.3390/VACCINES9050488
Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021). One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. The Journal of Clinical Investigation, 131(12), e149154. doi: 10.1172/JCI149154
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., Rubin, C., Freedman, L., Kreiss, Y., & Regev-Yochay, G. (2021). Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 385(24), e84. doi: 10.1056/NEJMOA2114583
Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y., Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X. L., … Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, 26(6), 845–848. doi: 10.1038/S41591-020-0897-1
Lozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., del Pino-Molina, L., Bravo-Gallego, L. Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., Lopez-Hoyos, M., Iribarren, M. E., Portoles, J., Rojo-Portoles, M. P., Ojeda, G., Cervera, I., Gonzalez-Perez, M., Bodega-Mayor, I., Montes-Casado, M., … Ochando, J. (2021). Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Reports, 36(8). doi: 10.1016/J.CELREP.2021.109570
Lozano-Rodríguez, R., Valentín-Quiroga, J., Avendaño-Ortiz, J., Martín-Quirós, A., Pascual-Iglesias, A., Terrón-Arcos, V., Montalbán-Hernández, K., Casalvilla-Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., García-Pérez, J., Cascajero, A., García-Garrido, M. Á., Balzo-Castillo, Á. del, Peinado, M., Gómez, L., Llorente-Fernández, I., Martín-Miguel, G., Herrero-Benito, C., … López-Collazo, E. (2022). Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 38(2), 110235. doi: 10.1016/J.CELREP.2021.110235
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., Mendelson, E., Ziv, A., Huppert, A., Rubin, C., Freedman, L., & Kreiss, Y. (2021). BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. The Lancet Respiratory Medicine, 9(9), 999–1009. doi: 10.1016/S2213-2600(21)00220-4
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020 586:7830, 586(7830), 589–593. doi: 10.1038/s41586-020-2639-4
Oliveira-Silva, J., Reis, T., Lopes, C., Batista-Silva, R., Ribeiro, R., Marques, G., Pacheco, V., Rodrigues, T., Afonso, A., Pinheiro, V., Araújo, L., Rodrigues, F., & Antunes, I. (2022). Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine, 40(4), 650–655. doi: 10.1016/J.VACCINE.2021.12.014
Pozzi, C., Azzolini, E., & Rescigno, M. (2023). Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination. The European Physical Journal Plus 2023 138:2, 138(2), 1–7. doi: 10.1140/EPJP/S13360-023-03732-9
Prendecki, M., Clarke, C., Brown, J., Cox, A., Gleeson, S., Guckian, M., Randell, P., Pria, A. D., Lightstone, L., Xu, X. N., Barclay, W., McAdoo, S. P., Kelleher, P., & Willicombe, M. (2021). Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet, 397(10280), 1178–1181. doi: 10.1016/S0140-6736(21)00502-X
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A. K., Grützner, J., Boesler, C., Rosenbaum, C., … Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020 586:7830, 586(7830), 594–599. doi: 10.1038/s41586-020-2814-7
Sedegah, M., Porter, C., Goguet, E., Ganeshan, H., Belmonte, M., Huang, J., Belmonte, A., Inoue, S., Acheampong, N., Malloy, A. M. W., Hollis-Perry, M., Jackson-Thompson, B., Ramsey, K. F., Alcorta, Y., Maiolatesi, S. E., Wang, G., Reyes, A. E., Illinik, L., Sanchez-Edwards, M., … Hollingdale, M. R. (2022). Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. PLOS ONE, 17(10), e0276241. doi: 10.1371/JOURNAL.PONE.0276241
Seraceni, S., Zocca, E., Cervone, T. E., Tomassetti, F., Polidori, I., Valisi, M., Broccolo, F., Calugi, G., Bernardini, S., & Pieri, M. (2022). T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers. Diseases, 10(3), 49. doi: 10.3390/DISEASES10030049
Sette, A., & Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. In Cell (184), 4, 861–880. Elsevier B.V. doi: 10.1016/j.cell.2021.01.007
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., … Jansen, K. U. (2021). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 385(19), 1761–1773. doi: 10.1056/NEJMOA2110345
Tormo, N., Navalpotro, D., Martínez-Serrano, M., Moreno, M., Grosson, F., Tur, I., Guna, M. R., Soriano, P., Tornero, A., & Gimeno, C. (2022). Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. Diagnostic Microbiology and Infectious Disease, 102(4), 115573. doi: 10.1016/J.DIAGMICROBIO.2021.115573
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021). Differences in the concentration of anti-sars-cov-2 igG antibodies post-covid-19 recovery or post-vaccination. Cells, 10(8), 1952. doi: 10.3390/CELLS10081952/S1
Tripp, R. A., Abdel-Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Al Meslamani, A. Z., Hayajneh, W., Alwahadneh, A. M., Hamadi, S., Abu-Qatouseh, L., Awad, R., Al Nsour, M., Alhariri, A., Shnewer, K., Da’ssan 12, M., Obeidat, N. M., Nusair, K. E., Jalamdeh, M. S., Hawari, F., … Aburuz, S. (2023). Real-World Effectiveness of Four Types of COVID-19 Vaccines. Vaccines 2023, 11(5), 985. doi: 10.3390/VACCINES11050985
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., Marson, B., Craxford, S. J., Kelly, A., Aithal, G. P., Vijay, A., Tighe, P. J., Ball, J. K., Valdes, A. M., & Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational
Medicine, 13(609), 847. doi: 10.1126/scitranslmed.abj0847
Vassilaki, N., Gargalionis, A. N., Bletsa, A., Papamichalopoulos, N., Kontou, E., Gkika, M., Patas, K., Theodoridis, D., Manolis, I., Ioannidis, A., Milona, R. S., Tsirogianni, A., Angelakis, E., & Chatzipanagiotou, S. (2021). Impact of age and sex on antibody response following the second dose of covid-19 bnt162b2 mrna vaccine in greek healthcare workers. Microorganisms, 9(8), 1725. doi: 10.3390/MICROORGANISMS9081725/S1
Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., … Gruber, W. C. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 383(25), 2439–2450. doi: 10.1056/NEJMOA2027906
Wei, J., Pouwels, K. B., Stoesser, N., Matthews, P. C., Diamond, I., Studley, R., Rourke, E., Cook, D., Bell, J. I., Newton, J. N., Farrar, J., Howarth, A., Marsden, B. D., Hoosdally, S., Jones, E. Y., Stuart, D. I., Crook, D. W., Peto, T. E. A., Walker, A. S., … Cunningham, C. (2022). Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine, 28(5), 1072–1082. doi: 10.1038/s41591-022-01721-6
Wei, J., Stoesser, N., Matthews, P. C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Howarth, A., Marsden, B. D., Hoosdally, S., Jones, E. Y., Stuart, D. I., Crook, D. W., Peto, T. E. A., Pouwels, K. B., … Lee, J. (2021). Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology, 6(9), 1140–1149. doi: 10.1038/s41564-021-00947-3
WHO Coronavirus (COVID-19) Dashboard. (2023, January 16). World Health Organization. Retrieved from https://covid19.who.int/
Zalewska, M., Fus, W., Konka, A., Wystyrk, K., Bochenek, A., Botor, H., Fronczek, M., Zembala-John, J., & Adamek, B. (2022). An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. Vaccines, 10(9), 1546–1546. doi: 10.3390/VACCINES10091546
Zhang, Q., Liu, Z., Moncada-Velez, M., Chen, J., Ogishi, M., Bigio, B., Yang, R., Arias, A. A., Zhou, Q., Han, J. E., Ugurbil, A. C., Zhang, P., Rapaport, F., Li, J., Spaan, A. N., Boisson, B., Boisson-Dupuis, S., Bustamante, J., Puel, A., … Zhang, X. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 370(6515). doi: 10.1126/SCIENCE.ABD4570
Zhong, D., Xiao, S., Debes, A. K., Egbert, E. R., Caturegli, P., Colantuoni, E., & Milstone, A. M. (2021). Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA, 326(24), 2524–2526. doi: 10.1001/JAMA.2021.19996
Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., Austin, J., Brown, R., Skelly, D., Gillson, N., Dobson, S. L., Cross, A., Sandhar, G., Kilby, J. A., Tyerman, J. K., … Chalk, J. (2022). T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe, 3(1), e21–e31. doi: 10.1016/S2666-5247(21)00275-5
Buonfrate, D., Piubelli, C., Gobbi, F., Martini, D., Bertoli, G., Ursini, T., Moro, L., Ronzoni, N., Angheben, A., Rodari, P., Cardellino, C., Tamarozzi, F., Tais, S., Rizzi, E., Degani, M., Deiana, M., Prato, M., Silva, R., & Bisoffi, Z. (2021). Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clinical Microbiology and Infection, 27(12), 1845–1850. doi: 10.1016/j.cmi.2021.07.024
Chen, Z., & John Wherry, E. (2020). T cell responses in patients with COVID-19. Nature Reviews Immunology, 20(9), 529–536. doi: 10.1038/s41577-020-0402-6
Claro, F., Silva, D., Rodriguez, M., Rangel, H. R., & de Waard, J. H. (2021). Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 111, 261–266. doi: 10.1016/J.IJID.2021.07.070
Cocomazzi, G., Piazzolla, V., Squillante, M. M., Antinucci, S., Giambra, V., Giuliani, F., Maiorana, A., Serra, N., & Mangia, A. (2021). Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers. Vaccines, 9(8), 913. doi: 10.3390/VACCINES9080913
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., Nagata, B. M., Andersen, H., Martinez, D. R., Noe, A. T., Douek, N., Donaldson, M. M., Nji, N. N., Alvarado, G. S., Edwards, D. K., … Graham, B. S. (2020). Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 383(16), 1544–1555. doi: 10.1056/NEJMoa2024671
Demonbreun, A. R., Sancilio, A., Velez, M. P., Ryan, D. T., Saber, R., Vaught, L. A., Reiser, N. L., Hsieh, R. R., D’Aquila, R. T., Mustanski, B., McNally, E. M., & McDade, T. W. (2021). Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine, 38, 101018. doi: 10.1016/j.eclinm.2021.101018
Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J. C., Frias, E. C., Stewart, J. L., Van Eyk, J. E., Braun, J. G., Cheng, S., & Sobhani, K. (2021). Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine, 27(6), 981–984. doi: 10.1038/s41591-021-01325-6
Fraley, E., Lemaster, C., Khanal, S., Banerjee, D., Pastinen, T., Grundberg, E., Selvarangan, R., & Bradley, T. (2022). The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clinical Infectious Diseases, 75(1), e902–e904. doi: 10.1093/CID/CIAB850
Gelanew, T., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Tefer, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., Bayih, A. G., Taffesse, F. G., Mihret, A., & Abdissa, A. (2022). A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individuals. Research Square, 10(6). doi: 10.21203/RS.3.RS-1250175/V1
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., Thorsteinsdottir, B., Kristjansdottir, S., Birgisdottir, K., Kristinsdottir, A. M., Sigurdsson, M. I., Arnadottir, G. A., Ivarsdottir, E. V., Andresdottir, M., Jonsson, F., … Stefansson, K. (2020). Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine, 383(18), 1724–1734. doi: 10.1056/NEJMOA2026116
Hasan, A., Al-Ozairi, E., Al-Baqsumi, Z., Ahmad, R., & Al-Mulla, F. (2021). Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, Volume 10, 63–85. doi: 10.2147/itt.s280706
Holder, K. A., Ings, D. P., Harnum, D. O. A., Russell, R. S., & Grant, M. D. (2022). Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. Npj Vaccines 2022 7:1, 7(1), 1–13. doi: 10.1038/s41541-022-00546-1
Ivanova, E. N., Devlin, J. C., Buus, T. B., Koide, A., Shwetar, J., Cornelius, A., Samanovic, M. I., Herrera, A., Mimitou, E. P., Zhang, C., Desvignes, L., Odum, N., Smibert, P., Ulrich, R. J., Mulligan, M. J., Koide, S., Ruggles, K. V., Herati, R. S., & Koralov, S. B. (2021). SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. MedRxiv. doi: 10.1101/2021.04.20.21255677
Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516–527. doi: 10.1038/s41586-020-2798-3
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G., Jurczyszak, D., Matthews, J. C., … Simon, V. (2021). Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New England Journal of Medicine, 384(14), 1372–1374. doi: 10.1056/NEJMC2101667
Lange, A., Borowik, A., Bocheńska, J., Rossowska, J., & Jaskuła, E. (2021). Immune Response to COVID-19 mRNA Vaccine—A Pilot Study. Vaccines, 9(5), 488. doi: 10.3390/VACCINES9050488
Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021). One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. The Journal of Clinical Investigation, 131(12), e149154. doi: 10.1172/JCI149154
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., Rubin, C., Freedman, L., Kreiss, Y., & Regev-Yochay, G. (2021). Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 385(24), e84. doi: 10.1056/NEJMOA2114583
Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y., Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X. L., … Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, 26(6), 845–848. doi: 10.1038/S41591-020-0897-1
Lozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., del Pino-Molina, L., Bravo-Gallego, L. Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., Lopez-Hoyos, M., Iribarren, M. E., Portoles, J., Rojo-Portoles, M. P., Ojeda, G., Cervera, I., Gonzalez-Perez, M., Bodega-Mayor, I., Montes-Casado, M., … Ochando, J. (2021). Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Reports, 36(8). doi: 10.1016/J.CELREP.2021.109570
Lozano-Rodríguez, R., Valentín-Quiroga, J., Avendaño-Ortiz, J., Martín-Quirós, A., Pascual-Iglesias, A., Terrón-Arcos, V., Montalbán-Hernández, K., Casalvilla-Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., García-Pérez, J., Cascajero, A., García-Garrido, M. Á., Balzo-Castillo, Á. del, Peinado, M., Gómez, L., Llorente-Fernández, I., Martín-Miguel, G., Herrero-Benito, C., … López-Collazo, E. (2022). Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 38(2), 110235. doi: 10.1016/J.CELREP.2021.110235
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., Mendelson, E., Ziv, A., Huppert, A., Rubin, C., Freedman, L., & Kreiss, Y. (2021). BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. The Lancet Respiratory Medicine, 9(9), 999–1009. doi: 10.1016/S2213-2600(21)00220-4
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020 586:7830, 586(7830), 589–593. doi: 10.1038/s41586-020-2639-4
Oliveira-Silva, J., Reis, T., Lopes, C., Batista-Silva, R., Ribeiro, R., Marques, G., Pacheco, V., Rodrigues, T., Afonso, A., Pinheiro, V., Araújo, L., Rodrigues, F., & Antunes, I. (2022). Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine, 40(4), 650–655. doi: 10.1016/J.VACCINE.2021.12.014
Pozzi, C., Azzolini, E., & Rescigno, M. (2023). Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination. The European Physical Journal Plus 2023 138:2, 138(2), 1–7. doi: 10.1140/EPJP/S13360-023-03732-9
Prendecki, M., Clarke, C., Brown, J., Cox, A., Gleeson, S., Guckian, M., Randell, P., Pria, A. D., Lightstone, L., Xu, X. N., Barclay, W., McAdoo, S. P., Kelleher, P., & Willicombe, M. (2021). Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet, 397(10280), 1178–1181. doi: 10.1016/S0140-6736(21)00502-X
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A. K., Grützner, J., Boesler, C., Rosenbaum, C., … Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020 586:7830, 586(7830), 594–599. doi: 10.1038/s41586-020-2814-7
Sedegah, M., Porter, C., Goguet, E., Ganeshan, H., Belmonte, M., Huang, J., Belmonte, A., Inoue, S., Acheampong, N., Malloy, A. M. W., Hollis-Perry, M., Jackson-Thompson, B., Ramsey, K. F., Alcorta, Y., Maiolatesi, S. E., Wang, G., Reyes, A. E., Illinik, L., Sanchez-Edwards, M., … Hollingdale, M. R. (2022). Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. PLOS ONE, 17(10), e0276241. doi: 10.1371/JOURNAL.PONE.0276241
Seraceni, S., Zocca, E., Cervone, T. E., Tomassetti, F., Polidori, I., Valisi, M., Broccolo, F., Calugi, G., Bernardini, S., & Pieri, M. (2022). T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers. Diseases, 10(3), 49. doi: 10.3390/DISEASES10030049
Sette, A., & Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. In Cell (184), 4, 861–880. Elsevier B.V. doi: 10.1016/j.cell.2021.01.007
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., … Jansen, K. U. (2021). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 385(19), 1761–1773. doi: 10.1056/NEJMOA2110345
Tormo, N., Navalpotro, D., Martínez-Serrano, M., Moreno, M., Grosson, F., Tur, I., Guna, M. R., Soriano, P., Tornero, A., & Gimeno, C. (2022). Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. Diagnostic Microbiology and Infectious Disease, 102(4), 115573. doi: 10.1016/J.DIAGMICROBIO.2021.115573
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021). Differences in the concentration of anti-sars-cov-2 igG antibodies post-covid-19 recovery or post-vaccination. Cells, 10(8), 1952. doi: 10.3390/CELLS10081952/S1
Tripp, R. A., Abdel-Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Al Meslamani, A. Z., Hayajneh, W., Alwahadneh, A. M., Hamadi, S., Abu-Qatouseh, L., Awad, R., Al Nsour, M., Alhariri, A., Shnewer, K., Da’ssan 12, M., Obeidat, N. M., Nusair, K. E., Jalamdeh, M. S., Hawari, F., … Aburuz, S. (2023). Real-World Effectiveness of Four Types of COVID-19 Vaccines. Vaccines 2023, 11(5), 985. doi: 10.3390/VACCINES11050985
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., Marson, B., Craxford, S. J., Kelly, A., Aithal, G. P., Vijay, A., Tighe, P. J., Ball, J. K., Valdes, A. M., & Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational
Medicine, 13(609), 847. doi: 10.1126/scitranslmed.abj0847
Vassilaki, N., Gargalionis, A. N., Bletsa, A., Papamichalopoulos, N., Kontou, E., Gkika, M., Patas, K., Theodoridis, D., Manolis, I., Ioannidis, A., Milona, R. S., Tsirogianni, A., Angelakis, E., & Chatzipanagiotou, S. (2021). Impact of age and sex on antibody response following the second dose of covid-19 bnt162b2 mrna vaccine in greek healthcare workers. Microorganisms, 9(8), 1725. doi: 10.3390/MICROORGANISMS9081725/S1
Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., … Gruber, W. C. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 383(25), 2439–2450. doi: 10.1056/NEJMOA2027906
Wei, J., Pouwels, K. B., Stoesser, N., Matthews, P. C., Diamond, I., Studley, R., Rourke, E., Cook, D., Bell, J. I., Newton, J. N., Farrar, J., Howarth, A., Marsden, B. D., Hoosdally, S., Jones, E. Y., Stuart, D. I., Crook, D. W., Peto, T. E. A., Walker, A. S., … Cunningham, C. (2022). Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine, 28(5), 1072–1082. doi: 10.1038/s41591-022-01721-6
Wei, J., Stoesser, N., Matthews, P. C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Howarth, A., Marsden, B. D., Hoosdally, S., Jones, E. Y., Stuart, D. I., Crook, D. W., Peto, T. E. A., Pouwels, K. B., … Lee, J. (2021). Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology, 6(9), 1140–1149. doi: 10.1038/s41564-021-00947-3
WHO Coronavirus (COVID-19) Dashboard. (2023, January 16). World Health Organization. Retrieved from https://covid19.who.int/
Zalewska, M., Fus, W., Konka, A., Wystyrk, K., Bochenek, A., Botor, H., Fronczek, M., Zembala-John, J., & Adamek, B. (2022). An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. Vaccines, 10(9), 1546–1546. doi: 10.3390/VACCINES10091546
Zhang, Q., Liu, Z., Moncada-Velez, M., Chen, J., Ogishi, M., Bigio, B., Yang, R., Arias, A. A., Zhou, Q., Han, J. E., Ugurbil, A. C., Zhang, P., Rapaport, F., Li, J., Spaan, A. N., Boisson, B., Boisson-Dupuis, S., Bustamante, J., Puel, A., … Zhang, X. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 370(6515). doi: 10.1126/SCIENCE.ABD4570
Zhong, D., Xiao, S., Debes, A. K., Egbert, E. R., Caturegli, P., Colantuoni, E., & Milstone, A. M. (2021). Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA, 326(24), 2524–2526. doi: 10.1001/JAMA.2021.19996
Published
2023-10-12
How to Cite
MOHAMMED, D. I., & SULAIMAN, A. A. (2023). DIFFERENCES IN IFN-GAMMA AND SARS-COV-2 SPECIFIC IgG LEVEL IN mRNA BNT162B2 (PFIZER-BIONTECH) VACCINATED NAIVE AND COVID-19 RECOVERED INDIVIDUALS FROM ZAKHO DISTRICT, DUHOK, IRAQ. Journal of Duhok University, 26(2), 289-301. https://doi.org/10.26682/sjuod.2023.26.2.25
Section
Pure and Engineering Sciences
It is the policy of the Journal of Duhok University to own the copyright of the technical contributions. It publishes and facilitates the appropriate re-utilize of the published materials by others. Photocopying is permitted with credit and referring to the source for individuals use.
Copyright © 2017. All Rights Reserved.
